Cambridge Investment Research Advisors, Inc. Blueprint Medicines Corp Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2017 Feb 22, 2018	SELL	$62.91 - $88.32 $220,185 - $309,120	-3,500 Closed	0 $0
Q3 2017 Nov 07, 2017	BUY	$42.37 - $69.67 $148,295 - $243,845	3,500	3,500 $244,000

Others Institutions Holding BPMC

# of Institutions

351

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

Vanguard Group Inc Valley Forge, PA

6.68M
Shares

$605 Million
0.01% of portfolio
Black Rock Inc. New York, NY

6.65M
Shares

$601 Million
0.02% of portfolio
Price T Rowe Associates Inc Baltimore, MD

5.39M
Shares

$487 Million
0.06% of portfolio
Wellington Management Group LLP Boston, MA

3.96M
Shares

$359 Million
0.07% of portfolio
State Street Corp Boston, MA

2.77M
Shares

$250 Million
0.01% of portfolio

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account